General Announcement::Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
09-May-2019 11:52:04
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris
Announcement Reference
SG190509OTHRG5QY
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
09/05/2019 09:20:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris , an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, in Patients Aged 6 to Under 12 Years

Attachments

PR_SGX_09.05.2019.pdf
Total size =284K